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Preclinical pharmacokineticsThe in vitro metabolism and in vivo pharmacokinetic (PK) properties of DNDI-VL-2098, a potential oral
agent for Visceral Leishmaniasis (VL) were studied and used to predict its human pharmacokinetics.
DNDI-VL-2098 showed a low solubility (10 lM) and was highly permeable (>200 nm/s) in the Caco-2
model. It was stable in vitro in liver microsomes and hepatocytes and no metabolite was detectable in
circulating plasma from dosed animals suggesting very slow, if any, metabolism of the compound.
DNDI-VL-2098 was moderate to highly bound to plasma proteins across the species tested (94–98%).
DNDI-VL-2098 showed satisfactory PK properties in mouse, hamster, rat and dog with a low blood clear-
ance (<15% of hepatic blood ﬂow except hamster), a volume of distribution of about 3 times total body
water, acceptable half-life (1–6 h across the species) and good oral bioavailability (37–100%). Allometric
scaling of the preclinical PK data to human gave a blood half-life of approximately 20 h suggesting that
the compound could be a once-a-day drug. Based on the above assumptions, the minimum efﬁcacious
dose predicted for a 50 kg human was 150 mg and 300 mg, using efﬁcacy results in the mouse and ham-
ster, respectively.
 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Visceral Leishmaniasis (VL) is a tropical disease caused by pro-
tozoan parasites of the genus Leishmania and it is transmitted by
the bite of certain species of the sand ﬂy. Also called Kala Azar,
the disease is endemic in parts of north-eastern India, sub-Saharan
Africa, parts of the Mediterranean, and South America. The disease
has world-wide distribution in Asia, East Africa, South America and
the Mediterranean regions. It kills 200,000–300,000 people a year
in the Indian subcontinent alone and is also greatly debilitating
to those who survive the infection.
Currently, pentavalent antimonials, amphotericin B adminis-
tered through IV route, and paramomycin administered through
IM route are the only ﬁrst-line treatments for VL. Resistance to
antimonials has reached 60% in Bihar state in India (Sundar et al.,
2000, 2012) whereas amphotericin is expensive to procure and
must be given as an IV infusion in a clinical setting. Paramomycin
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used as an oral treatment in India, Columbia, Brazil, and Germany
but major concerns exist over patient safety, compliance and sub-
optimal use leading to development of resistance (Olliaro et al.,
2005; Romero and Boelaert, 2010; Van Griensven et al., 2010).
There is thus an urgent need for a new oral and cost-effective
treatment.
The Leishmania parasite resides predominantly in the liver and
spleen. Oral administration has a particular advantage for VL as
blood from the intestine containing orally absorbed drug ﬁrst
reaches the liver, the site of the parasite, prior to entry into the
general circulation.
DNDI-VL-2098 was recently identiﬁed as a potent anti-
leishmanial compound as a result of an effort by the Drugs for
Neglected Diseases initiative (DNDi) to screen compounds originally
synthesized as antitubercular agents by the TB Alliance. The
compound is a nitro-imidazo-oxazole and the (R)-enantiomer (Fig. 1)
was selected for advanced evaluation. Other nitro-heterocyclic
compounds (e.g. 5- and 2- nitroimidazoles and 5-nitrofurans) are
effective against various protozoan and bacterial infections in humans
and animals. Although nitro groups in compounds are sometimes
associated with mutagenic characteristics, DNDI-VL-2098 has
been shown to be non-mutagenic in the Ames test.
DNDI-VL-2098 was potent in vitro in a macrophage amastigote
model against several strains including the standard Leishmania
donovani strain, an Indian antimony resistant strain (DD8,
IC50 = 0.025 lM), and against recently isolated clinical strains from
Africa (IC50 = 0.7–2.6 lM). In vivo, in both an acute mouse model of
the disease (50 mg/kg for 5 days; greater than 99% parasite inhibi-
tion) and in a chronic hamster model, DNDI-VL-2098 showed
greater than 85% parasite inhibition. In this latter model DNDI-
VL-2098 consistently showed greater efﬁcacy and longer duration
of effect than the racemate and the (S)-enantiomer (Gupta et al.,
2013). This greater efﬁcacy in a stringent animal model of leish-
maniasis justiﬁed the choice of (R)-enantiomer for advanced
evaluation.
Studies using a chiral bioanalytical assay showed that in vitro in
microsomes and hepatocytes, and in vivo in blood following dosing,
(R)-DNDI-VL-2098 does not undergo chiral interconversion to the
(S)-enantiomer.
As part of the preclinical evaluation an extensive characteriza-
tion of the in vitro and in vivo preclinical pharmacokinetic proper-
ties of (R)-DNDI-VL-2098 was performed.
2. Methods
2.1. Chemicals
DNDI-VL-2098 was synthesized at Advinus Therapeutics Lim-
ited, Bangalore, India. The Caco-2 cell line (human colon carcinoma
epithelial cell line) was obtained from ATCC (HTB-37, Manassas,
USA) and cells were used at passage number 40. Corning Trans-
well ﬁlters 12-well, HBSS, HEPES, glucose and sodium bicarbonate
were obtained from Sigma Aldrich (Bangalore, India). Liver micro-
somes, hepatocytes, hepatocyte isolation kits, Waymouth’s media
were purchased from Xenotech LLC (Kansas, USA). Puriﬁed recom-
binant CYP450 isozymes, CYP1A2, CYP2C9, CYP2C19, CYP2D6 andFig. 1. Structure of DNDI-VL-2098.CYP3A4 were purchased from BD Biosciences (Woburn, USA). For
the blood to plasma concentration ratio study, freshly collected
mouse, rat and dog blood was obtained from in-house animals.
Human blood was obtained from the Blood Bank (Bangalore, India).
For the protein binding study, a 96-well equilibrium dialyser with
150 lL half-cell capacity (HTDialysis, Gales Ferry, USA) employing
12–14,000 Dalton molecular weight cut-off membranes was used.
Standard substrates, metabolites, inhibitors, NADPH and deuter-
ated analytical internal standards used for the CYP inhibition study
were obtained from Sigma–Aldrich (Bangalore, India), BD Biosci-
ences (Woburn, USA) and TRC (Toronto, Canada).
2.2. Animal husbandry and handling
All animal studies had the approval of the Institutional Animal
Ethics Committee of Advinus Therapeutics Ltd. (an Association for
Assessment and Accreditation of Laboratory Animal Care accredited
facility) and were in accordance with the guidelines of the Commit-
tee for the Purpose of Control and Supervision of Experiments on
Animals (Government of India). Animals were acclimatized in study
rooms for at least three days prior to dosing. Hamsters and mice
were housed in polypropylene cages (3 per cage, marked for identi-
ﬁcation), rats were housed singly and dogs were housed in individ-
ual pens maintained in controlled environmental conditions
(22 ± 3 C; 40–70% Relative Humidity; 10–15 fresh air change
cycles/h) with 12 h light and dark cycles. All animals were bred
in-house except hamsters which were obtained from the Central
Drugs Research Institute, Lucknow, India. Hamsters, mouse and rats
were given Ssniff Rodent pellet food (ssniff Spezialdiäten GmbH,
Germany) ad libitum and dogs were given Pedigree standard dog
chow (manufactured by Effem India Private Limited, India) 300 g
once a day. Good quality water passed through activated charcoal
ﬁlter and exposed to UV rays was provided ad libitum throughout
the study to all animals.
In hamsters and mice, blood samples were collected through
retro-orbital plexus using a sparse sampling design. In rats and
dogs, a serial sampling design was used with blood samples with-
drawn through jugular vein in rats and cephalic vein in dogs. In
rats, surgery was performed 48 h before study conduct and no sur-
gery was performed in dogs.
2.3. In vivo pharmacokinetic studies
2.3.1. Formulations
The IV solution vehicle comprised 20% (v/v) N-methyl-2-pyrro-
lidinone (NMP) and 40% (v/v) polyethylene glycol 400 (PEG-400) in
100 mM citrate buffer pH 3. The PO vehicle comprised 7% (v/v)
Tween 80 and 3% (v/v) ethanol in water for hamster and mouse
studies. Oral solutions in rat and dog used the same vehicle as
IV. Suspension formulations comprised 0.08% (v/v) Tween 80 in
0.5% (w/v) sodium carboxymethyl cellulose (medium viscosity).
The IV dose volume was 1 mL/kg for hamsters, rats and dog and
2 mL/kg for mice. The oral dose volume was 10 mL/kg for hamsters
and mice, 5–10 mL/kg for rats and 2–5 mL/kg for dogs. Formula-
tions were prepared on the day of dosing.
2.3.2. Surgery in rats
Rats were anesthetized using 1 mL/kg body weight of a mixture
of ketamine (40 mg/mL) and xylazine (4 mg/mL). The depth of
anesthesia was assessed by sensory and motor responses. Rats
were placed in supine position and a 2 cm ventral cervical skin
incision was made on the right side. Tissues were cleaned to visu-
alize jugular vein following which a sterile PE-50 cannula was
inserted into the vein and secured in place with a suture. The can-
nula was exteriorized through the scapulae. Skin incisions were
sutured, sodium heparin (5000 IU/mL) was ﬂushed through the
R. Mukkavilli et al. / European Journal of Pharmaceutical Sciences 65 (2014) 147–155 149cannula and stoppered using stainless steel pin. Every day patency
was assessed to ensure no blocking of cannula.
2.3.3. Dosing
For IV bolus dose administration, hamsters and mice were
dosed through the tail vein, rats through the jugular vein and dogs
through the saphenous vein. The oral dose was administered by
gavage for all animals.
2.3.4. PK studies
Studies were performed in healthy male golden Syrian hamsters
(30 g), Swiss Albino mice (30–40 g), Sprague Dawley rats (250–
300 g) and Beagle dogs (10–13 kg). Hamsters and mice were fasted
4 h prior to dosing and food was provided 4 h post dose. Rats and
dogs were fasted overnight and were provided food 4 h post dose.
A sparse sampling design was used in hamsters and mice (n = 3
per time point). Serial blood sampling was used for rat (parallel
groups; n = 4) anddog (crossover; n = 3). In hamster, approximately,
100 lL blood samples was collected (K2EDTA anticoagulant,
20 lL/mL, 200 mM) at 0.083 (only IV), 0.25, 0.5, 1, 2, 4, 6, 12 and
24 h post-dose. In mouse and rat, blood samples were collected at
0.083 (only IV), 0.25, 0.5, 1, 2, 4, 6, 8, 10, 24, 48, and 72 h (only rat,
not mouse) post-dose. In the dog, blood samples were collected at
0.083 (only IV), 0.25, 0.5, 1, 2, 4, 8, 10, 24, 48, and 72 h post-dose.
Studies in dog using corn oil suspension, samples were collected
at 0, 0.25, 0.5, 1, 2, 3, 6, 12, 24, 48, 72 and 120 h following single oral
dose administration (QD); following BID dosing (dose administration
at 0 and 8 h), samples were collected at 0, 0.25, 0.5, 1, 1.5, 2, 3, 6, 8,
8.25, 8.50, 9.00, 9.5, 10, 11, 14, 16, 24, 48, 72, 96 and 120 h. In each
case a 75 lL aliquot of blood was mixed with 75 lL of 0.1 M HCl,
vortex-mixed and centrifuged (2600g, 5 min), and the supernatant
was stored below 60 C until analysis.
2.3.5. Pharmacokinetic analysis
Pharmacokinetic parameters were calculated using non-com-
partmental analysis tool of validated WinNonlinsoftware (Version
5.2). The area under the concentration time curve (AUClast and
AUCinf) was calculated by linear trapezoidal rule. The peak concen-
tration (Cmax) and time for the peak concentration (Tmax) were the
observed values. The elimination rate constant value (kel) was
obtained by linear regression of the log-linear terminal phase of
the concentration–time proﬁle using at least 3 non-zero declining
concentrations in terminal phase with a correlation coefﬁcient of
>0.8. The terminal half-life value (t1/2) was calculated using the
equation 0.693/kel. Allometric methods were used to predict
human blood clearance, volume of distribution and half-life
(Chaturvedi et al., 2001; Mehmood and Balian, 1996; Sharma and
McNeill, 2009).
2.4. In vitro studies
2.4.1. Solubility of DNDI-VL-2098 by UV spectrometry
Solubility of DNDI-VL-2098 was assessed up to 100 lM by spik-
ing dimethylsulfoxide (DMSO) stock solutions (10 lL, duplicate)
into 990 lL buffer in a 96-well plate and placing at room temper-
ature for 2 h. Calibration standards were prepared by spiking 5 lL
of DMSO stock solutions into 995 lL acetonitrile:buffer (1:1) mix-
ture. Following centrifugation (1700g, 20 min, 25 C) the superna-
tant was diluted 1:1 with acetonitrile and analyzed using a Tecan
M200 UV spectrophotometer.
2.4.2. Caco-2 permeability
Permeability of DNDI-VL-2098 (10 lM) was determined in api-
cal to basolateral (A–B) and basolateral to apical (B–A) directions.
Transport studies were conducted 21 days post seeding in 12-well
Transwell inserts. Following pre-incubation in HBSS-HEPES bufferin an orbital shaker (37 C, 5% CO2, 30 min), trans-epithelial electric
resistance (TEER) values were measured and only those inserts
with values above 300X cm2 were considered for assay. HBSS-
HEPES buffer was removed and DNDI-VL-2098 spiked HBSS-HEPES
buffer (1% ﬁnal DMSO concentration) was added to each donor
compartment in triplicate. Blank HBSS-HEPES buffer containing
1% DMSO was added to the receiver compartment. Samples were
withdrawn from the receiver chamber at 30, 60, 90, and 120 min,
and from the donor chamber at 0 and 120 min. TEER values were
measured after completion of assay to ensure monolayer integrity.
At the end of the experiment, cells were washed with cold buffer
and lysed with acetonitrile to assess cell accumulation and esti-
mate the recovery. Apparent permeability (Papp), efﬂux ratio
(Papp(B–A)/Papp(A–B)), cell accumulation (concentration in buffer and
acetonitrile wash) and recovery (total amount recovered/initial
amount added) were calculated. Rhodamine-123 (substrate for P-
gp) was run as positive control.
2.4.3. Microsomal stability
Microsomes from males of golden Syrian hamster, CD-1 mouse,
Sprague–Dawley rat, and Beagle dog, and mixed gender human
(pool of 50) were used for assays. Incubations (1 mL) consisted of
liver microsomes (0.5 mg/mL), NADPH (2 mM) and 50 mM phos-
phate buffer (pH 7.4). Following pre-incubation (10 min, 37 C),
reactions were initiated by adding DNDI-VL-2098 (0.5 lM). Sam-
ples (50 lL) were withdrawn at 0, 3, 6, 9, 12, 15, 18, 21, 27 and
30 min and quenched with 50 lL acetonitrile containing internal
standard. Concomitant NADPH-free control incubations were
made similarly with samples collected at 0 and 30 min. Verapamil
(hamster, mouse and dog liver microsomes) and diclofenac (rat
and human liver microsomes) were concomitantly used as positive
control substrates.
2.4.4. Stability in hepatocytes
Hepatocyte suspensions (CD-1 mouse, Wistar rat, Beagle dog,
human; male) containing 106 cells/mL were used for the incuba-
tions. Following pre-incubation of cell suspension (995 lL,
10 min, 37 C, 5% CO2), reactions were initiated by addition of
5 lL DNDI-VL-2098 stock solution (ﬁnal concentration in assay
was 0.5 lM). Samples (100 lL) were taken at 0, 5, 15, 30, 60, and
90 min, and quenched with 100 lL acetonitrile. Hepatocyte-free
control incubations were prepared by spiking 5 lL of DNDI-VL-
2098 into 995 lL of Waymouth’s media, and aliquots (100 lL)
were taken at 0 and 90 min. A cocktail mixture containing phenac-
etin, diclofenac, 7-hydroxycoumain, bufuralol and midazolam was
concomitantly used as positive control substrates.
2.4.5. CYP phenotyping
Incubations (1 mL) consisted of puriﬁed isozyme (50 pmol and
100 pmol, CYP1A2, 2C9, 2C19, 2D6 and 3A4), NADPH (2 mM) and
50 mM phosphate buffer (pH 7.4). After pre-incubation (10 min,
37 C), reactions were initiated by adding DNDI-VL-2098
(0.5 lM). Samples (100 lL) were taken at 0, 10, 20, 30, 40, 50,
and 60 min and quenched with 100 lL acetonitrile. NADPH-free
incubations were made similarly with samples at 0, 30 and
60 min. 7-ethoxyresoruﬁn, diclofenac, omeprazole, dextromethor-
phan and midazolam were concomitantly used as positive control
substrates for CYP1A2, 2C9, 2C19, 2D6 and 3A4, respectively.
2.4.6. Blood to plasma concentration ratio
Fresh blood (1 mL) was spiked with DNDI-VL-2098 to produce
0.3, 3, 30 lg/mL (0.08% DMSO). After gentle inversion, for the t0
time point, a 50 lL aliquot was hemolyzed by adding 50 lL 1% for-
mic acid and snap-frozen. A second 200 lL aliquot was taken to
generate plasma, 50 lL of which was mixed with 50 lL 1% formic
acid and snap-frozen. The remaining blood sample was incubated
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and 60 min.
2.4.7. Plasma protein binding
Plasma was spiked with DNDI-VL-2098 to produce 0.3, 3, 30 lg/
mL (0.08%DMSO). After gentle inversion, six replicates of 50 lL each
were collected at t0 to determine spiking accuracy, and another
500 lL sample was incubated in a microfuge tube (4 h, 37 C, 5%
CO2) to assess stability. Binding was determined by adding 120 lL
of DNDI-VL-2098 spiked plasma to one half-cell (donor, n = 6) of
equilibrium dialyser and 120 lL buffer to the receiver compart-
ment. The assembled dialyzer was incubated (37 C, 5% CO2,
120 rpm) for 4 h, after which plasma and buffer samples were
recovered from each half-cell and samples were analyzed. Diclofe-
nac was concomitantly used as a positive control compound.
2.4.8. CYP inhibition
Buffer, CYP substrates and microsomes (0.15 mg/mL except
0.25 mg/mL for CYP2C19 and 0.10 mg/mL for CYP3A-midazolam)
were mixed and aliquots were transferred into a 96-well plate.
CYP isozyme-speciﬁc probe substrates used were CYP1A2 (phenac-
etin, 45 lM), CYP2C9 (Diclofenac, 10 lM), CYP2C19 (S-mepheny-
toin, 55 lM), CYP2D6 (dextromethorphan, 10 lM), and CYP3A
(midazolam, 5 lM). DNDI-VL-2098 stock solutions were spiked
(1 lL) to achieve the ﬁnal target inhibitor concentrations (0.012,
0.024, 0.049, 0.098, 0.195, 0.39, 0.78, 1.56, 3.125, 6.25, and
12.5 lM). Following pre-incubation (5 min, 37 C), reactions were
initiated by adding 20 lL of 20 mMNADPH and the plate was incu-
bated at 37 C. At preset time points (5 min for CYP3A-midazolam,
7 min for CYP2C9 & CYP2D6, 10 min for CYP1A2, and 40 min for
CYP2C19), the reactions were quenched with acetonitrile, or 1%
formic acid:acetonitrile 70:30 for CYP1A2. All experiments were
run in triplicate (n = 3). Deuterated metabolite internal standards
were added and in situ production of the corresponding CYP
isozyme-speciﬁc metabolite (CYP1A2-acetaminophen, CYP2C9-4-
hydroxydiclofenac, CYP2C19-4-hydroxymephenytoin, CYP2D6-
dextrorphan, CYP3A-1-hydroxymidazolam) was determined.
a-napthoﬂavone, sulfaphenazole, benzylnirvanol, quinidine and
ketoconazole were concomitantly run as positive control inhibitors
for CYPs 1A2, 2C9, 2C19, 2D6 and 3A4, respectively. The concentra-
tion of test inhibitor required for 50% reduction in themeasured iso-
zyme activity (IC50) was estimated using GrapPad Prism software.
2.4.9. Samples for routes of biotransformation
Samples for in vitro biotransformation were obtained following
incubation of DNDI-VL-2098 (10 lM) with microsomes in presence
of cofactors, and with hepatocytes for up to 120 min as described
for metabolic stability. Samples for in vivo biotransformation were
oral PK blood samples at 4, 6 and 8 h post dose from mouse
(50 mg/kg), rat (500 mg/kg) and dog (50 mg/kg). All samples were
precipitated with acetonitrile, vortex-mixed and centrifuged
(1700g, 10 min) and the supernatants were analyzed for Phase I
and Phase II metabolites.
2.5. Bioanalysis
All in vivo and in vitro samples were analyzed for DNDI-VL-2098
and internal standard (DNDI-VL-2075, a structural analog) content
using a high performance liquid chromatography (HPLC, Shimadzu
Prominence, Japan) tandem mass spectrometric (API4000, Applied
Biosystems, USA) method. Positive-ion electron spray ionization
mode was used and MRM transitions of 360.20/175.00 for DNDI-
VL-2098 and 370.20/241.20 for DNDI-VL-2075 (5 lg/mL) were
monitored. An isocratic HPLC method with a 4 min run time was
employed for analysis. The mobile phase comprised 5 mM ammo-
nium formate and acetonitrile 20:80 (v/v) with 0.05% formic acidand the ﬂow rate was 0.6 mL/min. Separation was achieved using
Kromasil C8 column (4.6  50 mm, 5 l, Chromatographie Service,
USA) maintained at 40 C employing an injection volume of 10 lL
for in vivo samples and 5 lL for in vitro samples.2.5.1. In vivo samples
In preliminary studies, DNDI-VL-2098 showed some instability
in plasma from different species. Acidiﬁcation of blood samples
from dosed animals with an equal volume of 0.1 M HCl resolved
the issue, as bench-top stability of greater than 5 h was achieved;
therefore all concentrations were determined in blood. Blood sam-
ples were extracted using liquid–liquid extraction (LLE) with
methyl tert-butyl ether (MTBE). A 50 lL aliquot of blood, internal
standard (20 lL) and potassium dihydrogen phosphate buffer
(100 mM, 50 lL) and 1.25 mL of MTBE were vortex mixed and then
centrifuged at 2500g for 5 min. A 1 mL aliquot of supernatant was
evaporated under ﬂow of nitrogen gas at 50 C until dryness, and
the residue was reconstituted with 200 lL of mobile phase before
analysis.
The lower limit of quantiﬁcation (LLOQ) was 5 ng/mL and the
assay was linear over a 1000-fold concentration range. All samples
were processed along with calibration curve and quality control
samples. An acceptance criterion of ±15% was used for all calibra-
tion curve (CC), and quality control (QC) standards except for LLOQ
sample where ±20% was the acceptance criteria.2.5.2. In vitro samples
Samples were processed by protein precipitation with acetoni-
trile for all assays except the blood to plasma concentration ratio
assay where LLE using MTBE was employed. Processed samples
were analyzed for peak area ratios. Samples from studies of protein
binding were quantitated using a calibration curve. CC, QC and
study samples were prepared using a mixed matrix approach by
mixing 5 lL of DMSO (blank/CC/QC), 5 lL of plasma (blank/stabil-
ity/donor samples) and 50 lL of buffer (blank/receiver samples)
followed by protein precipitation using acetonitrile containing
internal standard.
Studies using a chiral bioanalytical assay showed that in vitro in
microsomes and hepatocytes, and in vivo in pharmacokinetic
plasma samples, (R)-DNDI-VL-2098 does not undergo chiral inter-
conversion to the (S) enantiomer (Bioanalytical manuscript under
preparation).2.5.3. Routes of biotransformation
All samples were scanned using a PDA detector (SPD-M20A),
LC/MS and LC/MS/MS using positive (MH+), negative (MH-) (Q1)
and product ion (MS/MS) scan. A full scan analysis was performed
from m/z 100 to m/z 1000. Possible metabolite peaks were identi-
ﬁed in positive Q1 scan after assessing for matrix interference
using test item free control samples and subsequently conﬁrmed
using the fragmentation pattern (MS/MS scan). Samples were run
using Kromasil C18 column (150  4.6 mm, 5 l, Chromatographie
Service, USA) maintained at 40 C, employing a linear gradient
comprising 0.1% formic acid in water and 0.1% formic acid in ace-
tonitrile, with a 30 min run time. An injection volume of 20 lL
was used with a ﬂow rate of 400 lL/min. The concentration of
organic phase was ﬁxed at 5% for the initial 6 min, linearly
increased to 95% over the next 15 min, held at 95% for the next
9 min, brought back to 5% over the next 2 min followed by equili-
bration for the next 4 min. The declustering potential was 60 V,
entrance potential was 10 V, collision energy for MS/MS was
23 eV, collision gas was 6 Psi, curtain gas was 20 Psi, ion gas 1
was 40 Psi, ion gas 2 was 50 Psi, ion spray voltage was 5500 V
and temperature was 500 C.
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3.1. In vivo pharmacokinetics and blood partitioning
The pharmacokinetics of DNDI-VL-2098 was determined in
blood as it was found to be unstable in plasma (bench top stability:
30% remaining over 3 h). The mean blood to plasma concentration
ratio (Cb/Cp) value ranged from 0.55 (human) to 1.24 (mouse) and
was similar across the concentration ranges tested (0.3–30 lg/mL,
Table 1). These data indicate that DNDI-VL-2098 does not partition
extensively into RBCs.
The concentration time proﬁles for DNDI-VL-2098 are shown in
Fig. 2. The compound was well distributed with a steady-state vol-
ume of distribution that was 3 times total body water (0.7 L/kg) in
the hamster, mouse and rat, and about 4 times total body water in
the dog. It showed a low intravenous blood clearance in vivo in
mouse, rat and dog, and a moderate clearance in the hamster.
When expressed as a percentage of the normal hepatic blood ﬂow
(QH), the blood clearance was about 40% in the hamster, 10% in the
mouse, 14% in the rat and 17% in the dog (Davies and Morris,
1993). The low in vivo clearance of DNDI-VL-2098 is consistent
with its high metabolic stability in vitro in liver microsomes and
hepatocytes, and its generally high oral bioavailability. The oral
bioavailability of DNDI-VL-2098 was good to excellent in all four
species (Table 2).3.2. Pharmacokinetic linearity
DNDI-VL-2098 showed close to dose proportional exposures in
rodents (Table 2). Oral exposure in hamster and mouse were deter-
mined across the 6.25–50 mg/kg range (doses tested for efﬁcacy)
using formulations identical to those used in efﬁcacy studies. In
both species, bioavailability was 100% at the lowest 6.25 mg/kg
dose, and in both species an 8-fold increase in dose (from 6.25 to
50 mg/kg) led to an 11-fold increase in exposure. In rat, oral expo-
sures were determined across the 5–500 mg/kg dose range (doses
tested in early safety studies) using a suspension in CMC. Here, a
100-fold increase in dose led to about a 100-fold increase in expo-
sure. Fig. 3a summarizes the relationship between dose and dose-
normalized AUCs (DNAUC) in various species following suspension
administration. The dose-normalized AUCs of DNDI-VL-2098 were
generally independent (within 2-fold) of the administered doses.
In the rat and dog, oral solution and suspension exposures were
determined at 5 mg/kg. In both species, the mean solution expo-
sure was higher than that with suspension (Fig. 3b). In the dog at
the higher dose of 50 mg/kg given as suspension, exposure did
not increase proportionally (Table 2). A similar ‘‘apparent solubility
limited absorption’’ did not occur in the rat where exposures
increased dose-proportionally up to 500 mg/kg given as suspen-
sion. This observation is consistent with DNDI-VL-2098 being aTable 1
In vitro blood to plasma concentration ratio of DNDI-VL-2098.
Blood/plasma concentration ratio (60 min)a
Concentration (lg/mL) Mouseb Ratc Dogd Humane
0.3 1.29 0.82 0.74 0.52
3 1.31 0.68 0.75 0.59
30 1.13 1.08 0.75 0.54
Average 1.24 0.86 0.75 0.55
a Mean, n = 2; Blood collected from males, pool of at least 3 animals/concentra-
tion Anticoagulant: 200 mM K2EDTA, 20 lL per mL of blood.
b Swiss Albino mice.
c Sprague–Dawley rat.
d Beagle dog.
e Asian.low solubility/high permeability compound, with the high perme-
ability overriding any limitation that low solubility may pose to
absorption, at least in the rat.
Because exposures increased proportionally with dose in the rat
at high doses, follow up studies were performed in the dog at higher
doses using a corn oil formulation. As solubility of DNDI-VL-2098
was less in water, an oil-based formulation using corn oil was eval-
uated. In this case, a 100-fold increase in dose from 5 mg/kg to
500 mg/kg, led to a 37-fold increase in exposure (AUClast). By using
a 500 mg/kg BID dosing (dosed 8 h apart; total dose 1000 mg/kg),
therewas a 50% increase in exposure (360 ± 36 lg h/mL;n = 3) com-
pared to that obtained at the 1250 mg/kg QD dose (246 ± 74 lg h/
mL; n = 3, Fig. 4).
3.3. Prediction of human PK and human efﬁcacious doses
The preclinical PK parameters were used to perform allometric
scaling to predict pharmacokinetics in humans. First, simple allo-
metric scaling of the clearance and volume of distribution data
was performed using Y = aWb, where Y is the parameter of interest,
and a and b are coefﬁcient and exponent of the allometric equation,
respectively, and W is body weight. The clearance exponent calcu-
lated with this approach was 0.9. Because it exceeded 0.7, the max-
imum lifespan potential (MLP (years) = (185.4) (Br0.636) (BW0.225))
approach was used (Mahmood, 2007). The MLP method gave esti-
mates of 1.69 mL/min/kg for blood clearance and 2.97 L/kg for vol-
ume of distribution for a 50 kg human (Fig. 5). These human
clearance and volume estimates gave an estimated blood half-life
(T½ = 0.693  Vss/CL) for DNDI-VL-2098 in humans of approxi-
mately 20 h, suggesting that the compound is likely to be a once-
a-day drug.
To predict human efﬁcacious doses, the model-independent
equation for clearance was used: Dose = AUC⁄CL/F, where AUC is
the targeted AUCinf at the ED99 from the preclinical animal model
studies. The following assumptions were made: (1) exposure
required for efﬁcacy in human will be similar to that at the ED99
in the preclinical efﬁcacy models of mice and hamsters, (2) expo-
sures in healthy mice and hamsters at their ED99 doses are similar
to those in the disease models, (3) human bioavailability will be
about 50%, and (4) the predicted human clearance from allometric
scaling is an accurate estimate of in vivo clearance. Based on the
above assumptions, the minimum efﬁcacious dose predicted for a
50 kg human was 150 mg and 300 mg, based on results for the
mouse and hamster, respectively (Table 3).
In addition to allometric scaling, the in vitro microsomal intrin-
sic clearance data of VL-2098 (<0.6 mL/min/g liver in mouse, rat,
dog and human) were also used to predict the hepatic clearance
(CLhep,in vitro). The prediction was based on the well-stirred model
with an assumed intrinsic clearance of 0.6 mL/min/g liver, and
used the measured unbound fraction at the highest tested concen-
tration. These results were compared with the observed clearance
CLtotal in vivo. In the mouse, the predicted CLhep,in vitro was 1.91 mL/
min/kg compared to the observed CLtotal of 9.37 mL/min/kg (2% and
10% of the hepatic blood ﬂow (Qh), respectively). In the rat, the pre-
dicted CLhep,in vitro was 1.34 mL/min/kg compared to the observed
CLtotal of 8.18 mL/min/kg, (2% and 15% of Qh, respectively). In the
dog, the predicted CLhep,in vitro was 0.82 mL/min/kg compared to
the observed CLtotal of 5.18 mL/min/kg (3% and 16% of Qh, respec-
tively). Thus, the predicted hepatic clearance using in vitro micro-
somal data results in an under-prediction of the actual total
clearance. This is consistent with the possibility of additional
non-Phase-I and/or non-hepatic routes of elimination for DNDI-
VL-2098 although such a conclusion will require demonstration
in future radiolabeled ADME studies. In human, the predicted
hepatic clearance from in vitro data was 0.84 mL/min/kg and allo-
metric scaling gave a CLtotal value of 1.69 mL/min/kg. Taken
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Fig. 2. Concentration–time proﬁles of DNDI-VL-2098 in pharmacokinetic studies in the hamster, mouse, rat and dog.
Table 2
In vivo pharmacokinetic parameter estimates.
Species Dose (mg/kg) Route Tmax (h) C0/Cmax (lg/mL) AUClast (lg h/mL) CLblood (mL/min/kg) Vss,blood (L/kg) T½ (h) F
Hamster 1 (Solution) IV 1.14 0.63 ± 0.02 25.98 2.00 1.19
6.25 (Suspension) PO 0.25 1.17 ± 0.99 4.49 ± 0.24 115
12.5 (Suspension) 0.50 2.36 ± 0.27 17.13 ± 0.84
25 (Suspension) 4.00 3.13 ± 0.16 29.80 ± 2.05
50 (Suspension) 4.00 4.93 ± 0.54 53.00 ± 2.82
Mouse 1 (Solution) IV 0.74 1.65 ± 0.10 9.37 1.98 2.94
6.25 (Suspension) PO 2.00 1.08 ± 0.33 13.10 ± 0.95 127
12.5 (Suspension) 4.00 2.43 ± 0.30 29.76 ± 1.79
25 (Suspension) 4.00 5.39 ± 1.12 77.23 ± 5.34
50 (Suspension) 6.00 8.39 ± 0.90 145.08 ± 17.30
Rat 1 (Solution) IV 0.56 ± 0.09 1.84 ± 0.34 8.18 ± 1.62 2.24 ± 0.53 3.44 ± 0.84
5 (Solution) PO 1.81 ± 2.79 0.86 ± 0.28 10.96 ± 2.58 119
5 (Suspension) 4.50 ± 1.91 0.57 ± 0.15 6.64 ± 1.04 72
50 (Suspension) 5.00 ± 1.15 7.13 ± 1.72 76.22 ± 8.44
100 (Suspension) 6.50 ± 1.00 9.99 ± 1.25 187.14 ± 91.10
200 (Suspension) 7.50 ± 1.91 12.75 ± 2.92 351.77 ± 68.80
500 (Suspension) 12.00 ± 8.16 16.90 ± 1.85 659.72 ± 176.96
Dog 1 (Solution) IV 0.62 ± 0.23 3.48 ± 1.86 5.18 ± 1.99 2.50 ± 1.55 6.05 ± 2.85
5 (Solution) PO 0.42 ± 0.14 0.80 ± 0.37 11.28 ± 7.41 79
5 (Suspension) 1.83 ± 1.89 0.38 ± 0.12 5.53 ± 1.54 39
50 (Suspension) 10.00 ± 12.17 0.88 ± 0.51 22.79 ± 23.75
Data from sparse sampling proﬁles for hamster and mouse expressed as mean ± SE using Bailer method; n = 3.
Data from serial sampling proﬁles for rat and dog expressed as mean ± SD; n = 4 for rat; n = 3 for dog.
152 R. Mukkavilli et al. / European Journal of Pharmaceutical Sciences 65 (2014) 147–155together, the half-life estimate using allometric scaling may repre-
sent a more conservative estimate than that using the in vitro
microsomal clearance.
3.4. In Vitro metabolism and disposition studies
3.4.1. Solubility and CaCo-2 permeability
DNDI-VL-2098 was soluble up to 10 lM in sodium phosphate
buffer (50 mM, pH 7.4) and it was highly permeable across theCaco-2 monolayer (Papp greater than 200 nm/s). The efﬂux ratio
was less than 2 indicating that the compound is not a substrate
for the efﬂux transporters Pgp and BCRP (Table 4).
3.4.2. Metabolic stability in vitro in liver microsomes, hepatocytes and
puriﬁed CYPs
DNDI-VL-2098 generally showed very low intrinsic clearance in
liver microsomes and hepatocytes (CLintr < 0.6 mL/min/kg; n = 3 in
all species except hamster microsomes); these data are consistent
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Fig. 3. Oral dose-normalized AUC (DNAUC) as a function of administered dose of
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hamster microsomes the CLintr was 2.5 ± 0.2 mL/min/g liver (low to
moderate), an observation consistent with its moderate in vivo
blood clearance (40% of hepatic blood ﬂow) in that species. The
CLintr of verapamil and diclofenac exceeded 5 mL/min/g liver, and
that of the cocktail of substrates used in hepatocytes matched his-
torical in-house values, indicating that all the preparations were
metabolically active.
DNDI-VL-2098 was stable in the tested recombinant human
CYPs using 50 pmol and 100 pmol CYP content (T½ > 60 min for
all isozymes, except CYP2C19 100 pmol where T½ = 43 min); this
observation is consistent with its high stability in microsomes
and hepatocytes. The t½ values of concomitantly run positive-
controls matched historical in-house values (7-ethoxyresoruﬁn:2.3 min, diclofenac: 3.8 min, omeprazole: 2.0 min, dextromethor-
phan: 0.8 min, testosterone: 11.5 min at 50 pmol CYP content).
3.4.3. Protein binding
DNDI-VL-2098 showed moderate to high binding (Table 5). The
unbound fraction was determined to be 3–6% across the species
tested. Results for the concomitantly run highly bound compound
diclofenac (percentage unbound 0.23 ± 0.10) matched the histori-
cal in-house values in this assay.
3.4.4. CYP inhibition
DNDI-VL-2098 did not inhibit CYP1A2, CYP2C9, CYP2D6 and
CYP3A4 at concentrations up to 12.5 lM (triplicate IC50 studies).
It did however inhibit CYP2C19 with an IC50 value of
0.47 ± 0.24 lM. IC50 values for concomitantly run positive control
inhibitors a-napthoﬂavone, sulfaphenazole, N-3-benzylnirvanol,
quinidine and ketoconazole (0.004 lM, 0.32 lM, 0.56 lM,
0.050 lM and 0.011 lM, respectively) matched the historical in-
house values in this assay.
3.4.5. Biotransformation of DNDI-VL-2098
A minor monooxygenation metabolite (M-I, 19.44 min) was
detected in mouse, rat and dog liver microsomes (<0.2% for mouse,
<0.1% for rat and <0.5% for dog assuming similar ionization) based
on peak area comparison of metabolite to parent peak, but it was
not detected in incubations with human liver microsomes. The
likely site of monooxygenation is in the triﬂuoromethoxyphenyl
ring (Fig. 1) based on the fragmentation pattern. The metabolite
was not detectable in mouse, rat, dog and human hepatocyte incu-
bations nor in circulating blood samples from mouse (oral 50 mg/
kg), rat (oral 500 mg/kg) and dog (oral 50 mg/kg). These results are
consistent with studies in liver microsomes and hepatocytes
indicating that DNDI-VL-2098 is stable in vitro. PA-824, a novel
4-nitroimidazole is currently in phase II clinical trial for tuberculo-
sis (TB) and a structural analog of DNDI-VL-2098, produces 4
Table 3
Estimated human efﬁcacious doses.
Species ED99 (mg/kg) Efﬁcacious AUC at ED99 (ng h/mL) Predicted human CL (mL/min/kg) Dose (AUC⁄CL/F)a (mg/kg) Dose for 50 kg human (mg)
Mouse 6.25 14,549 1.69 2.95 148
Hamster 25 30,047 1.69 6.10 305
a Human bioavailability (F) assumed to be 50%; ED99 data was generated at CDRI, Lucknow, India and used as such for predictions.
Table 4
Transepithelial transport of DNDI-VL-2098 across CaCo-2 Monolayer.
Compound Parameters A to B B to A
DNDI-VL-2098 Papp (nm/s) 226 ± 18 247 ± 41
Efﬂux ratio 1.1
Intracellular accumulation (%) 11 ± 0.4 18 ± 0.4
Mass Balance (%) 95 ± 1 105 ± 1
TEER (X cm2) before and after experiment >300 >300
Rhodamine-123 (positive control) Papp (nm/s) 7 ± 2 22 ± 2
Efﬂux Ratio 3
Intracellular accumulation (%) 5 ± 1 4 ± 1
Mass balance (%) 99 ± 3 90 ± 3
TEER (X cm2) before and after experiment >300 >300
Mean ± SD, n = 3 per assay.
Table 5
Plasma protein binding.
Plasma protein binding – (% bound)a
Concentration (lg/mL) Mouseb Ratc Dogd Humane
0.3 96.82 ± 0.27 94.62 ± 0.31 98.27 ± 0.25 97.39 ± 0.59
3 96.68 ± 0.06 94.12 ± 0.45 94.86 ± 0.31 94.26 ± 0.63
30 96.35 ± 0.55 94.28 ± 0.60 95.60 ± 0.78 94.40 ± 0.42
a Mean ± SD, n = 6; Blood collected from males, pool of at least 3 animals/subjects Anticoagulant: 200 mM K2EDTA, 20 lL per mL of blood.
b Swiss Albino mice.
c Sprague–Dawley rat.
d Beagle dog.
e Asian.
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major des-nitro metabolite, and seven metabolites with puriﬁed
Ddn (deazaﬂavin F420 dependent nitroreductase) and mycobacte-
rium tuberculosis (Dogra et al., 2011). No analogous metabolites
of DNDI-VL-2098 structurally similar to those of PA-824 were
detectable in in vitro and in vivo samples. In summary, DNDI-VL-
2098 is not extensively metabolized in preclinical species in vitro
and in vivo, and in human microsomes and hepatocytes in vitro.
To understand the disposition and excretion pathways of DNDI-
VL-2098, studies with 14C labeled DNDI-VL-2098 are planned.4. Discussion
DNDI-VL-2098 is a recently identiﬁed potent new oral lead
compound for Visceral Leishmaniasis that is currently under pre-
clinical development. Convenience of therapy (oral as opposed to
parenteral treatment) and patient compliance are important goals
for a successful new treatment for VL, particularly because it is
endemic in rural areas. As such, DNDI-VL-2098 represents a major
breakthrough for an unmet medical need. The studies described
here show that DNDI-VL-2098 possesses excellent preclinical
in vitro and in vivo pharmacokinetic properties in a variety of
rodent and non-rodent models. Allometric scaling of these data
predicts that the compound will have good pharmacokinetics in
humans and the predicted efﬁcacious human doses are amenable
to development.The in vitro microsomal intrinsic clearance of DNDI-VL-2098,
and its in vivo clearance in animal models showed a close relation-
ship. In vitro intrinsic clearance was very low in microsomes from
all species (<0.6 mL/min/g liver), except in the hamster where it
was moderately stable (2.5 mL/min/g liver) Rao et al., 2011. Simi-
larly, the in vivo blood clearance was low in the mouse, rat and
dog, and moderate in the hamster. In all of these cases, even if
the blood clearance was assumed to entirely reﬂect only hepatic
clearance, DNDI-VL-2098 would be predicted to have a low hepatic
extraction ratio (0.10, 0.14 and 0.17 in mouse, rat and dog, respec-
tively), and a moderate extraction ratio of 0.4 in hamster. These
data are consistent with generally good bioavailability of the com-
pound in vivo.
The results of the studies suggest that the efﬁcacy of DNDI-VL-
2098 seen in vivo in animal models (Gupta et al., 2013) results from
the potency and pharmacokinetic proﬁle of the parent compound,
rather than on any active metabolites. Whether assessed in micro-
somes, or in hepatocytes, or in blood samples from in vivo dosed
animals, DNDI-VL-2098 was metabolically stable and there was
consistently no evidence for production of any meaningful metab-
olite based on LC–MS/MS–UV detection. The samples for in vivo
biotransformation were taken following high oral doses leading
to high blood concentration of parent drug. The time points
selected for assessment (4–8 h post dose) adequately covered the
parent compound half-life (1–6 h). Therefore, inadequate analyti-
cal sensitivity or early collection points appears unlikely to affect
the ability to detect metabolites. Only one, very minor, mono-
oxygenation metabolite was detectable in liver microsomes from
R. Mukkavilli et al. / European Journal of Pharmaceutical Sciences 65 (2014) 147–155 155preclinical species (less than 0.5% of parent; likely mono-oxygena-
tion in the triﬂuoromethoxyphenyl ring (Rao et al., 2011) but not in
those from human. DNDI-VL-2098 was found to be 94–98% bound
to plasma proteins, but this extent of protein binding does not limit
its efﬁcacy. Taken together, the data suggest that the in vivo anti-
parasitic activity of DNDI-VL-2098 is related to circulating levels
of parent drug, and that during further toxicological and clinical
development quantiﬁcation of the parent compound DNDI-VL-
2098 will sufﬁce.
The oral absorption properties of DNDI-VL-2098 were generally
very good. The compound has a low aqueous solubility (about
10 lM at pH 7.4) and a high permeability (226 nm/s in Caco-2
cells). Its total polar surface area (tPSA) is 91 (6140 Å2) another
feature consistent with its good permeability characteristics
(Veber et al., 2002). It showed excellent bioavailability at low oral
doses in three rodent species (80–100%) consistent with its high
permeability and metabolic stability. Moreover, even at high toxi-
cologically relevant oral doses, oral suspension exposure in rats
increased linearly with dose over a 100-fold dose range (5 mg/kg
to 500 mg/kg) (Harisudhan et al., 2011). Taken together with its
low aqueous solubility and high permeability, these data suggest
that the high permeability of DNDI-VL-2098 overrides its poor
aqueous solubility and enables high oral bioavailability in rodents.
In dogs, oral bioavailability appears slightly lower (39–79%)
although providing adequate exposure. For a 100-fold increase in
dose from 5 mg/kg to 500 mg/kg, a 37-fold increase in exposure
was observed. The corn oil formulation was tested as a mean to
enhance exposure and QD and BID dosing were assessed. Corn oil
is also an accepted vehicle for early toxicity assessment. Following
500 mg/kg BID dosing in corn oil (1000 mg/kg/day), there was a
50% increase in exposure compared to a 1250 mg/kg QD dose.
These data indicate that the less than dose-proportional increase
in exposure in dogs can be circumvented by using appropriate for-
mulation and dosing frequency for toxicology studies. Importantly,
these proof-of-principle data with corn oil in dog suggest that, if
needed, other alternative formulation approaches with DNDI-VL-
2098 are likely to be similarly successful for human.
Overall the safety impact of any possible drug–drug interactions
with DNDI-VL-2098 appears acceptable. DNDI-VL-2098 did not
inhibit CYPs 1A2, 2C9, 2D6 and 3A4/3A5 in vitro and is unlikely
to cause drug–drug interactions mediated by these isozymes.
DNDI-VL-2098 did inhibit CYP2C19, for which substrates are com-
paratively limited as compared to the other major CYPs. They
include the proton pump inhibitors lansoprazole and omeprazole;
anti-epileptics such as diazepam, phenytoin, and phenobarbitone;
the tricyclic antidepressants amitriptyline and clomipramine; and
the nitrogen mustard alkylating agent cyclophosphamide. Addi-
tionally, the antiplatelet agent clopidogrel and the antimalarial
proguanil are converted to their active metabolite by CYP2C19
(Flockhart, 2007). DNDI-VL-2098 itself is very stable in vitro in
human liver microsomes, hepatocytes and recombinant CYPs sug-
gesting that its own clearance is unlikely to be affected by co-
administered drugs. In light of the lack of therapeutic options for
Visceral Leishmaniasis, the overall risk-proﬁle for CYP-mediated
drug–drug interactions therefore appears acceptable. Further stud-
ies are needed to characterize the nature of the CYP2C19 inhibition
as well its clinical relevance.
The pharmacokinetic properties of DNDI-VL-2098 in the pre-
clinical species suggest that it has the potential to be a once-a-
day drug. Its relatively long half-life in vivo in the various animal
species (t½ = 1.2 h in the hamster, 3 h in mouse, 3.5 h in rat and
about 6 h in the dog), result from a combination of a generally
low clearance and a moderate volume of distribution across spe-
cies. Allometric scaling of the preclinical pharmacokinetic data pre-
dicts a half-life in humans of about 20 h. The predicted humanefﬁcacious dose range of 150–300 mg for DNDI-VL-2098 makes it
amenable to further oral solid dosage form design for the upcom-
ing Phase 1 trials in humans.
5. Conclusions
DNDI-VL-2098, a lead for treatment of VL with excellent phar-
macokinetic properties was identiﬁed and developed. DNDI-VL-
2098 was assessed in pre-clinical species like mouse and hamster
(species for efﬁcacy models), and rat and dog (species for toxicol-
ogy). In general, DNDI-VL-2098 showed (A) low blood clearance
(<15% of hepatic blood ﬂow), (B) low volume of distribution (3
times total body water), (C) acceptable half-life and (D) good oral
bioavailability and with acceptable dose linearity. The predicted
human efﬁcacious doses are in the 150–300 mg range, making it
amenable to oral solid dosage form drug for upcoming Phase I tri-
als in human.
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